Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer

Simple item page
dc.date.accessioned2012-03-30T05:31:19Z
dc.date.available2012-03-30T05:31:19Z
dc.date.issued2011-09-23
dc.date.updated2012-03-30T05:31:19Z
dc.description.abstractAbstract Background Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica. Methods The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naand#239;ve CaP controls (group 2) and 170 hormone naand#239;ve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed. Results Mean and#177; sd, age of patients in group 1 (75and#177; 7.4 yrs) was significantly greater than groups 2 and 3 (67 and#177; 8.1 yrs; 65and#177;12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean and#177; sd, (-1.6and#177; 1.5) was significantly less than group 2 (-0.9and#177;1.1) and group 3 (-0.7and#177;1.4), p andlt;0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (pandlt;0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (pandlt;0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1). Conclusions ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.
dc.description.versionPeer Reviewed
dc.identifierhttp://dx.doi.org/10.1186/1750-9378-6-S2-S7
dc.identifier.citationInfectious Agents and Cancer. 2011 Sep 23;6(Suppl 2):S7
dc.identifier.urihttps://hdl.handle.net/2139/12613
dc.language.rfc3066en
dc.rights.holderet al.; licensee BioMed Central Ltd.
dc.titleBone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
dc.typeJournal Article

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
1750-9378-6-S2-S7.xml
Size:
45.5 KB
Format:
Extensible Markup Language
Download
Thumbnail Image
Name:
1750-9378-6-S2-S7.pdf
Size:
913.85 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

BioMed Central